Inventor · disambiguated record
Mary Erickson
Also filed as: ERICKSON MARY · ERICKSON MARY RUTH
21 granted patents·10 pending applications·224 citations·filing 2001–2022
95Inventor score
Files withSERONO GENETICS INST SA6AEGERION PHARMACEUTICALS INC4AMYLIN PHARMACEUTICALS LLC4GENSET SA4LEVY ODILE ESTHER4
Top patents by PatentIndex Score
31 records- 0196US8263545B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Sep 11, 2012·62 cites·3 claims
- 0295US8497240B2DPP-IV resistant GIP hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Jul 30, 2013·25 cites·11 claims
- 0392US6579852B2OBG3 globular head and uses thereof for decreasing body massGENSET SA·Filed 2001·Granted Jun 17, 2003·34 cites·2 claims
- 0490US8404637B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2006·Granted Mar 26, 2013·16 cites·12 claims
- 0590US6566332B2OBG3 globular head and uses thereof for decreasing body massGENSET SA·Filed 2001·Granted May 20, 2003·29 cites·2 claims
- 0689US6967091B2OBG3 globular head and uses thereof for decreasing body massGENSET SA·Filed 2002·Granted Nov 22, 2005·22 cites·29 claims
- 0786US6989367B2OBG3 globular head and uses thereofGENSET SA·Filed 2002·Granted Jan 24, 2006·14 cites·26 claims
- 0880US7393661B2Nucleic acids encoding OBG3 polypeptidesSERONO GENETICS INST SA·Filed 2005·Granted Jul 1, 2008·2 cites·132 claims
- 0979US2023115655A1Engineered polypeptides having enhanced duration of actionAMRYT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1078US9593154B2Engineered polypeptides having enhanced duration of actionAMYLIN PHARMACEUTICALS LLC·Filed 2013·Granted Mar 14, 2017·4 cites·10 claims
- 1178US7470669B2Isolated polypeptide comprising a leptin fragmentSERONO GENETICS INST SA·Filed 2005·Granted Dec 30, 2008·3 cites·17 claims
- 1277US7671024B2OBG3 globular head and uses thereofSERONO GENETICS INST SA·Filed 2008·Granted Mar 2, 2010·1 cites·60 claims
- 1374US9382304B2Engineered polypeptides having enhanced duration of action with reduced immunogenicityERICKSON MARY·Filed 2012·Granted Jul 5, 2016·6 cites·11 claims
- 1473US10087228B2Chimeric leptin polypeptide and method of using the sameAEGERION PHARMACEUTICALS INC·Filed 2015·Granted Oct 2, 2018·1 cites·7 claims
- 1571US7338787B2Nucleic acids encoding OBG3 globular head and uses thereofSERONO GENETICS INST SA·Filed 2004·Granted Mar 4, 2008·1 cites·30 claims
- 1670US9879063B2Engineered polypeptides having enhanced duration of action and reduced immunogenicityAEGERION PHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·1 cites·14 claims
- 1770US9133260B2GIP analog and hybrid polypeptides with selectable propertiesAMYLIN PHARMACEUTICALS LLC·Filed 2013·Granted Sep 15, 2015·1 cites·8 claims
- 1868US11535659B2Engineered polypeptides having enhanced duration of actionAMRYT PHARMACEUTICALS INC·Filed 2020·Granted Dec 27, 2022·0 cites·8 claims
- 1968US7928060B2Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using themAMYLIN PHARMACEUTICALS INC·Filed 2005·Granted Apr 19, 2011·1 cites·16 claims
- 2061US2013203661A1Highly soluble leptinsAMYLIN PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 2160US7348406B2Metabolic gene polynucleotides and polypeptides and uses thereofSERONO GENETICS INST SA·Filed 2002·Granted Mar 25, 2008·1 cites·15 claims
- 2255US8895498B2GIP and exendin hybrid polypeptidesLEVY ODILE ESTHER·Filed 2012·Granted Nov 25, 2014·0 cites·6 claims
- 2355US2013274182A1Engineered polypeptides having enhanced duration of actionASTRAZENECA PHARMACEUTICALS LP·Filed 2013·Application pending·0 cites
- 2454US2016137709A1Engineered polypeptides having enhanced duration of actionAEGERION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2552US2018305430A1Engineered Polypeptides Having Enhanced Duration of Action and Reduced ImmunogenicityAEGERION PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2650US2002058617A1OBG3 globular head and uses thereof for decreasing body massFiled 2001·Application pending·0 cites
- 2748US2013281374A1Dpp-iv resistant gip hybrid polypeptides with selectable propertiesASTRAZENECA PHARMACEUTICALS LP·Filed 2013·Application pending·0 cites
- 2848US2014256621A1Engineered poypeptides having enhanced duration of action and reduced immunogenicityERICKSON MARY·Filed 2012·Application pending·0 cites
- 2943US2017114114A1Engineered polypeptides having enhanced duration of actionAMYLIN PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 3039US7326678B2GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereofSERONO GENETICS INST SA·Filed 2002·Granted Feb 5, 2008·0 cites·14 claims
- 3136US2018344813A1Engineered polypeptides having enhanced duration of action with reduced immunogenicityERICKSON MARY·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mary Erickson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →